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Abstract:  
Introduction: The development of effective drugs for the treatment of diabetes is one of the urgent problems of modern medicine; 
we conducted pharmacokinetic studies of the innovative hypoglycemic drug - C7070, in rabbits and rats.  
Materials and Methods: The object of the study was substance C7070. Two methods of administration have been studied: intra-
venously and intragastrically. The concentration of C7070 is determined in blood plasma by a sensitive and selective HPLC 
method with tandem mass spectrometry detection. The range of detection was from 0.02 μg to 3876.00 μg in 1 ml of plasma in the 
animals under study. Chromatographic separation was performed on a 150 × 3.0 mm column of Zorbax Eclipce XDB C18 with a 
particle size of 3.0 μm (Agilent technologies, USA). To obtain stable results, a Zorbax Eclipce XDB C18 (Agilent technologies, 
USA) protection column of 12.5 × 3.0 mm with a particle size of 5.0 μm was used at 40 ° C for all analytical cycles. Ballast pro-
teins in the test solutions were precipitated with acetonitrile followed by extraction of the analyte with ultrasound.  
Results and its Discussion: With intragastric administration, the maximum concentration (Cmax) of C7070 in blood plasma 
reached, on average, in rabbits through (tmax) 60 ± 0.1 minutes, in rats after 170.0 ± 79.8 minutes and was 34.6 ± 7.3 μg/ml and 
17.6 ± 1.4 μg/ml, respectively. The half-life (t1/2) was prolonged and was 291.8 ± 17.1 minutes for rabbits and 225.2 ± 12.4 
minutes for rats. The absolute bioavailability (fa) of C7070 in rabbits was 78.2 ± 1.0%, in rats 18.1 ± 2.0%. When administered 
intravenously, Cmax C7070 in blood plasma averaged 123.1 ± 23.7 μg/ml in rabbits and 337.6 ± 40.5 μg/ml in rats. The half-life 
period (t1/2) was prolonged and amounted to 225.5 ± 15.9 minutes for rabbits and 154.1 ± 5.1 minutes for rats.  
The Conclusion: The pharmacokinetic characteristics of a potential hypoglycemic drug C7070 in animals (rats, rabbits) under 
two routes of administration, intra-gastrointestinal and intravenous, were studied. The parameters obtained can be useful for 
clinical application and further studies of C7070 drugs based on it. 
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INTRODUCTION: 
According to the world statistics, over the past 10 
years the number of people with diabetes mellitus 
(DM) has more than doubled and by the end of 2016 
it is about 420 million people. According to the fore-
casts of the International Diabetes Federation, by the 
year 2040, 642 million people will suffer from diabe-
tes. 
Taking this into account, the development of effec-
tive medicines for the treatment of diabetes is one of 
the urgent problems of modern medicine. 
The search for innovative molecules [0, 2] is an im-
portant task of pharmacology. In this case, their study 
should be carried out on pharmacological targets [0, 
0], in vivo models [0, 0], pharmacokinetic parameters 
[0] and clinical studies [0, 0]. 
One of the new developments in the treatment of dia-
betes is 3- (1H-benzimidazol-2-yl) -1.2.2-
trimethylcyclopentanecarboxylic acid (C7070) [0].  
 
Fig 1: Structural formula C7070 
 
Interest in this substance - a potential hypoglycemic 
drug for the treatment of diabetes is due to the fact 
that antagonists of imidazoline receptors are antihy-
pertensive drugs clonidine, moxonidine and rilmen-
idine, as well as an antidiabetic drug metformin. An-
tihypertensive drugs clonidine, moxonidine and ril-
menidine unlike 3- (1H-benzimidazol-2-yl) -1.2.2-
trimethylcyclopentanecarboxylic acid do not affect 
glycemic control. The antidiabetic drug metformin 
for safety (acute toxicity, lactic acidosis and other 
side effects), the breadth of the therapeutic index and 
the severity of antidiabetic properties is inferior to 
C7070. Unlike C7070, metformin has not been prov-
en: the ability to restore the physiological function of 
pancreatic β-cells, cerebroprotective and nootropic 
effects. 
 
The purpose of research - the study of the pharma-
cokinetics of potential hypoglycemic drug С7070 on 
animals (rats, rabbits). Материалы и методы 
исследования. 
 
The object of study - is substance C7070. Twelve 
rabbits (males weighing 3500 ± 20% g) and 12 rats 
(males weighing 350 ± 20% g) were included in the 
study. Adaptation time before the study was 8 days. 
In the study, animals were selected with no signs of 
abnormal appearance. The basic rules of maintenance 
and care are in accordance with the regulations given 
in the manual Guide for the care and use of laborato-
ry animals. The National Academy press. – Washing-
ton, D.C. 2011 [0].  
The following reagents were used in the work: sub-
stance C7070 (CJSC VladMiVa, RF, Belgorod), pha-
bomotizole (Sigma), formic acid (Panreac), ammoni-
um acetate (Panreac), methanol (Merk), acetonitrile 
for gradient chromatography (Merk), water 18.2 MΩ 
× cm, obtained with the Gene Pure system (Thermo 
Scientific, USA). 
Methods of research. To carry out pharmacokinetic 
studies, HPLC MS/MS was developed to determine 
the C7070 in the blood plasma of rats and rabbits and 
complete validation [0]. Methods of keeping up with 
modern requirements [0, Error! Reference source 
not found., 0].  
The determination of C7070 in blood plasma of rats 
and rabbits was carried out on a liquid chromatograph 
UltiMate 3000 LC (Thermo Fisher Scientific, USA) 
equipped with a thermostatable automatic dispenser, 
vacuum degasser, gradient pump, column thermostat. 
The analyte was detected on a Velos Pro mass spec-
trometer (Thermo Scientific, USA) with ionization in 
a heated electrospray (H-ESI-II). This equipment has 
already been used by us earlier [Error! Reference 
source not found.] in quantitative studies and has 
shown good results.  
Sample preparation. The preparation of the initial 
solutions of C7070 included several steps. In the first 
stage, a stock solution of C7070 in methanol with a 
concentration of 0.2% was prepared. In the second 
stage, C7070 solutions in methanol were prepared by 
dilution series to be added to standard solutions and 
quality control solutions with a concentration of 
0.00002%, 0.002% and 0.011%. 
A solution of the internal standard was used at the 
same level of concentrations - 0.1% in methanol. 
Calibration solutions were prepared at seven concen-
tration levels. 100 μl of plasma were placed in 1.5 ml 
Eppendorf tubes, aliquots of the starting solutions and 
100 μl of the internal standard solution were added, 
mixed, 0.1 ml of acetonitrile added, and mixed. Ex-
tracted C7070 in an ultrasonic bath for three minutes. 
After the sample was frozen at a temperature of -70 ° 
C. After thawing, it was centrifuged at 13,000 rpm 
and 4 ° C for 25 minutes. Thus, 14 solutions were 
prepared with seven levels of concentrations: 0.02 μg 
0.19 μg, 1.94 μg, 19.38 μg, 193.80 μg, 1938.00 μg 
and 3876.00 μg in 1 ml plasma. Each level was pre-
pared and analyzed twice. 
Quality control solutions (QC) were prepared similar-
ly to calibration solutions at two concentration levels 
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in two replicates. Thus, 4 solutions were prepared 
with two levels of concentrations - 0.19 μg (lower 
quality control - LQC) and 1938.00 (upper quality 
control - UQC) in 1 ml of plasma. 
The test solutions were prepared similarly to the cali-
bration solutions. 100 μl of plasma was placed in 1.5 
ml Eppendorf tubes, 100 μl of internal standard solu-
tion was added, mixed, 0.1 ml of acetonitrile added, 
and mixed. Extracted C7070 in an ultrasonic bath for 
three minutes. The samples were frozen at a tempera-
ture of -70 ° C. After thawing, the samples were cen-
trifuged at 13,000 rpm and 4 ° C for 25 minutes. 
Parameters HPLC-MS/MS. Chromatographic separa-
tion was carried out on a 150 mm × 3.0 mm column 
of Zorbax Eclipce XDB C18 (Agilent technologies, 
USA) with a particle size of 3.0 μm with a Zorbax 
Eclipce XDB C18 (Agilent technologies, USA) pro-
tection column of 12.5 × 3.0 mm with a particle size 
of 5.0 μm, at a temperature of 40 ° C. The parameters 
of the chromatographic system are presented in Table 
1. 
 
Table 1: Parameters of the chromatographic system 
 
UltiMate 3000 LC: 
Sample volume (μl): 2 
Mobile phase: 
 
Gradient according to the following program: 
Time, 
min 
Flow, 
ml / min 
5 mM Ammonium  
acetate + 
 0.1% Formic acid 
Acetonitrile, % 
Methanol, 
% 
0 0.4 80 20 0 
5.0 0.4 80 20 0 
8.5 0.4 75 10 15 
9.0 0.4 20 70 10 
11.0 0.4 20 70 10 
11.1 0.4 80 20 0 
12.5 0.4 80 20 0 
 
Retention times (min): 
C7070 - about 4.7; 
The internal standard - about 8.5. 
Injection time (min): 12.5 
Velos Pro: 
Tool: Velos Pro (Thermo Scientific, США) 
Ionization type: H-ESI  
Polarity: С7070 «+» 
Internal standard «+» 
Mass transfer: 
С7070 – 272.35→255.15; 
Internal standard – 307.41→114. 
Collision energy: С7070 – 42; 
 Internal standard – 19  
Voltage at source (V): 
С7070 – 3000 
Internal standard – 3000 
Source temperature (°C): 
С7070 –300 
Internal standard – 300 
Capillary temperature (°C): 
С7070 – 350 
Internal standard – 350 
Sheath gas pressure (Arb): 
С7070 – 60 
Internal standard –60 
Aux gas pressure (Arb): 
С7070 – 20 
Internal stan 
dard – 20 
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Protocol for the study of the pharmacokinetics of 
C7070 in rabbits. Twelve rabbits were pre-
catheterized into the right ear vein. Twelve hours 
before the experiment began, the animals were de-
prived of food, leaving free access to water. On the 
third day after the catheterization, the test substance 
was administered.  
With intravenous dosing, the test substance was ad-
ministered bolus to six rabbits in the ear vein as a 
solution of 26.7 mg/ml in propylene glycol at a dose 
of 26.7 mg/kg. Blood was collected through a cathe-
ter in a volume of 0.3 ml into polypropylene tubes 
containing 20 μl of 5% EDTA before injection, at 5, 
15, 30, 60, 120, 240, 480, 1440 minutes after admin-
istration. With intragastric dosing, the substance was 
administered with a probe in the form of a solution of 
26.7 mg/ml in propylene glycol at a dose of 26.7 
mg/kg. Blood was collected through a catheter in a 
volume of 0.3 ml into polypropylene tubes containing 
20 μl of 5% EDTA before injection, at 15, 30, 60, 
120, 240, 480, 1440 minutes after administration. The 
blood plasma was separated by centrifugation at 5600 
g for 10 min and stored until analysis at a temperature 
of -70 ° C. 
Protocol for the study of the pharmacokinetics of 
C7070 in rats. Twelve rats were pre-catheterized into 
the right jugular vein. For the operation, intraperito-
neal anesthesia was used: 10% zolletil: 2% xylazine = 
1: 5, 70 μl/100 g of body weight. Twelve hours be-
fore the experiment began, the animals were deprived 
of food, leaving free access to water. 
With intravenous dosing, the test substance was ad-
ministered bolus to six rats in the tail vein as a 50 
mg/ml solution in propylene glycol at a dose of 50 
mg/kg. Blood was collected through a catheter in a 
volume of 0.2 ml into polypropylene tubes containing 
20 μl of 5% EDTA before injection, at 5, 15, 30, 60, 
120, 240, 480, 1440 minutes after administration. 
With intragastric dosing, the substance was adminis-
tered with a probe in the form of a solution of 50.0 
mg/ml in propylene glycol at a dose of 50 mg/kg. 
Blood was taken through a 0.2 ml catheter into poly-
propylene tubes containing 20 μl of 5% EDTA before 
injection, at 15, 30, 60, 120, 240, 480, 1440 minutes 
after administration. The blood plasma was separated 
by centrifugation at 5600 g for 10 min and stored 
until analysis at a temperature of -70 ° C. 
 
RESULTS OF THE STUDY: 
The main pharmacokinetic parameters were calculat-
ed on the basis of experimentally obtained data. Con-
centrations of C7070 in the investigated objects were 
calculated from calibration curves. The sharply high-
lighted results (outliers) in animals at each time point 
were detected using the Grubbs statistical criterion 
[0].  
Pharmacokinetics of C7070 in rabbits. Figure 2 
shows the average pharmacokinetic profiles of C7070 
for intragastric and intravenous routes of administra-
tion to rabbits (n = 6) at a dose of 26.7 mg/kg. 
                           
 
Fig 2: The average concentration-time dependence for two routes of administration of C7070 intragastric 
(P.O.) and intravenous (I.V.) in a dose of 26.7 mg/kg in rabbits 
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Table 2 presents the main pharmacokinetic characteristics of C7070 obtained when the drug was administered in-
tragastrically and intravenously to rabbits (n = 6) at a dose of 26.7 mg/kg. 
Table 2: The average pharmacokinetic characteristics of C7070 for intragastric and intravenous admin-
istration to rabbits (n = 6) at a dose of 26.7 mg/kg. 
Indicator 
The route of administration 
P.O.  I.V. 
AUC(0-1440), (μg/ml) × min 14113.4±1916.9 18179.0 ±1037.5 
AUC(0-∞),(μg/ml) × min 15326.5±1840.4 18946.7±1122.7 
Сmax, μg/ml 34.6±7.3 123.1±23.7 
tmax, min 60±0.1 - 
t1/2, min 291.8±17.1 225.5±15.9 
MRT, min 421.0±24.7 325.3±23.0 
fa, % 78.2±1.0 - 
 
The results show that, with intragastric administra-
tion, the maximum concentration (Cmax) of C7070 in 
rabbit blood plasma reached an average of 60 ± 0.1 
minutes and was 34.6 ± 7.3 μg/ml. The area under the 
pharmacokinetic curve (AUC (0-1440)) from the time of 
entry to the time of the last blood sampling was 
14113.4 ± 1916.9 (μg/ml) × min for intragastric ad-
ministration and 18179.0 ± 1037.5 (μg/ml) × min for 
intravenous administration. The half-life period (t1/2) 
was prolonged and was 291.8 ± 17.1 minutes for in-
tragastric introduction, 225.5 ± 15.9 minutes for in-
travenous administration. The mean retention time 
(MRT) of C7070 was 421.0 ± 24.7 minutes for intra-
gastric administration and 325.3 ± 23.0 minutes for 
intravenous administration. The absolute bioavaila-
bility (fa) of C7070 for intragastric dosing in rabbits 
was 78.2 ± 1.0 %. 
Pharmacokinetics in rats. Figure 3 shows the average 
pharmacokinetic profiles of C7070 for intragastric 
and intravenous routes of administration to rats (n = 
6) at a dose of 50.0 mg/kg. 
                               
Fig 3: The average concentration-time dependence for two routes of administration of C7070 intragastric 
(P.O.) and intravenous (I.V.) in a dose of 50.0 mg/kg in rats 
 
Table 3 presents the main pharmacokinetic characteristics of C7070 obtained by administering the drug intra-
gastrointestinal and intravenously to rats (n = 6) at a dose of 50.0 mg/kg. 
Table 3: The average pharmacokinetic characteristics of C7070 for intragastric and intravenous ad-
ministration to rats (n = 6) at a dose of 50.0 mg / kg 
Indicator 
The route of administration 
P.O. I.V. 
AUC(0-1440), (μg/ml) × min 6592.7±577.3 36777.1± 2888.9 
AUC(0-∞),(μg/ml) × min 6963.5±622.7 37857.7± 3180.1 
Сmax, μg/ml 17.6±1.4 337.6± 40.5 
tmax, min 170.0±79.8 - 
t1/2, min 225.2±12.4 154.1±5.1 
MRT, min 325.0±17.9 222.3±7.3 
fa, % 18.1±2.0 - 
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The results show that with intragastric administration 
of Cmax C7070 in rat blood plasma averaged 170.0 ± 
79.8 minutes and was 17.6 ± 1.4 μg/ml. AUC (0-1440) 
from the time of entry to the time of the last blood 
sampling was 6592.7 ± 577.3 (μg/ ml) × min for in-
tragastric administration and 36777.1 ± 2888.9 
(μg/ml) × min for intravenous administration. t1/2 con-
tinuous, was 291.8 ± 17.1 minutes for intragastric 
administration and 225.5 ± 15.9 minutes for intrave-
nous administration. MRT C7070 was 421.0 ± 24.7 
minutes for intragastric administration and 325.3 ± 
23.0 minutes for intravenous administration. The ab-
solute bioavailability (fa) of C7070 for intragastric 
dosing in rabbits was 78.2 ± 1.0%.  
Analysis of these results shows that the C7070 is well 
absorbed from the gastrointestinal tract, retained in 
the body for a long time. From the point of view of 
developing a new antidiabetic drug, this is an un-
doubted plus. There is the possibility of using a sim-
ple and affordable dosage form for oral administra-
tion with a pronounced therapeutic effect for a long 
time. 
It is worth noting that in the course of the work, there 
were interspecies differences in pharmacokinetic pa-
rameters with intragastric dosing. Of the many al-
leged causes, it is necessary to identify the mecha-
nisms of absorption in the body. According to the 
physical and chemical properties of C7070 has a poor 
solubility in water. It is well known that this is the 
basic barrier rate of absorption for such a drug. For 
most drugs, absorption occurs through passive trans-
cellular and paracellular transport, limited due to tight 
contacts between cells. Absorption occurs in a thin 
layer of intestinal epithelial cells, which covers the 
luminal surface of the intestinal wall. Thus, the speed 
and completeness of the absorption will directly hang 
from the surface area [0]. With such results, it can be 
assumed that interspecies differences are associated 
with the difference in the areas of the surface of the 
intestinal wall in rabbit and rat. However, variations 
within one species of animals have low values (not 
more than 20%). This suggests that when a person is 
dosed, the result will be predictable [0, 0].  
 
CONCLUSION: 
In the course of the work, the pharmacokinetic char-
acteristics of the potential hypoglycemic drug C7070 
in animals (rats, rabbits) were successfully studied by 
two routes of administration, intragastric and intrave-
nous. It was found that the drug is well absorbed 
from the gastrointestinal tract, it is well distributed 
into tissues and is excreted unchanged. The parame-
ters obtained can be useful for clinical application 
and further studies of preparations C7070 on its basis. 
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